Opko Health Inc

NASDAQ:OPK   3:59:54 PM EDT
3.70
0.00 (0.00%)
4:20:04 PM EDT: $3.67 -0.03 (-0.81%)
Products

Pfizer And OPKO Announce Extension Of U.S. FDA Review Of Biologics License Application Of Somatrogon

Published: 09/24/2021 20:33 GMT
Opko Health Inc (OPK) - Pfizer and Opko Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency.
Pfizer Inc - PDUFA Goal Date Has Been Extended by Three Months to January 2022, As a Result of Pfizer's Submission of Additional Data to Original Bla.